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Abstract: Primary treatment for glaucoma relies on chronic instillation (daily) of intraocular 
pressure (IOP) lowering eye drops. Present study tends to develop and assess a novel 
sustained release bimatoprost loaded nanovesicular (BMT-NV) - thermosensitive in-situ 
gelling implant (BMT-NV-GEL-IM), for subconjunctival delivery. 
BMT-NVs developed using novel composition and method of preparation, 
(IPA/700/DEL/2014) and industrially viable methodology were characterised and evaluated 
comprehensively for ocular suitability. Their incorporation into an in-situ gelling formula 
was safe (in vitro and in vivo) and stable upon sterilization. Autoclavability was an important 
consideration, as a preservative-free, single-use BMT-NV-GEL-IM will avoid side- effects 
associated with repetitive application of drops containing preservatives like benzalkonium 
chloride (BAK). An extended in vitro release of BMT (80.23%) was observed for 10 days 
while the IOP lowering effect extended over 2 months with single subconjunctival injection 
of BMT-NV-GEL-IM in rats. No clinical signs of irritation, inflammation, or infection were 
observed in any injected eye, throughout the study, as also confirmed by histology.  
Furthermore, single administration of BMT-NV-GEL as topical drop lowered the IOP over 5 
days. Presence of significant diffuse fluorescence in confocal microscopy of internal eye 
tissues post-in vivo application, as subconjunctival implant, even after 2 month and eye drops 
upto1 week provide direct evidence of successful sustained delivery. We thus provide an 
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improved modality for antiglaucoma medication in patients who are challenged to adhere to a 
regimen of daily eye drops.  
Keywords:  Glaucoma, nanomedicine, sustained delivery, fluorescence, cytotoxicity, ocular. 
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1. INTRODUCTION 
Glaucoma comprehends a heterogenic group of ophthalmic diseases that damage the optic nerve 
by degenerating retinal ganglion cells (RGC), leading to progressively increasing vision loss. It 
is a chronic ocular disease majorly inflicting the old and requires long-term therapy sometimes 
extending through entire lifetime. According to World Health Organization (WHO) statistics, 
glaucoma is an age-related disease, which is the second leading cause of blindness in the world. 
Worldwide, more than 60 million individuals are afflicted by this condition, and the number is 
expected to increase to more than 100 million by 2040 [1]. Elevation of intraocular pressure 
(IOP) if corrected suitably can slow or stop the progression of the disease [2, 3]. Both surgical 
and pharmacological treatment options are available. Latter involves treatment with medicated 
drops that reduce the production of aqueous humor (viz. β-adrenergic receptor antagonists and 
carbonic anhydrase inhibitors) and/or improve its outflow (viz. prostaglandins, sympatho- and 
parasympathomimetics, and α2-adrenergic receptor agonists) [4]. Prostaglandins/prostamides 
(PG/PM) are fast emerging, highly effective first-line therapy for glaucoma. They are able to 
control IOP, primarly by increasing uveoscleral outflow via remodeling of the cilliary body [5]. 
Out of this group, bimatoprost (BMT) a PM, is pharmacologically superior as it lowers IOP by 
dual pathways of increasing both the uveoscleral and the trabecular aqueous humor outflow [6] .  
BMT (0.03% solution) is generally well-tolerated, cost effective [7] and thermally stable [5] 
amongst all prostaglandins. It is slightly soluble (0.0187 mg/ml), lipophilic (Log P=3.2) 
molecule, with a large molecular weight (415.56Da). BMT marketed eye drop (0.03%) 
effectively lower IOP, by 6.5–8.9 mmHg, over long-term use in glaucoma and ocular 
hypertension (OHT) [8]. A 0.03% bimatoprost, eye drops have been associated with conjunctival 
congestion probably due to nitric oxide-mediated vasodilatation in the conjunctiva [6], which 
was reduced significantly when BMT was used at a lower concentration of 0.01% (Lumigan, 
Allergan, Inc.). Latter formulation contains higher (4 fold) BAK concentration which is proposed 
to improve corneal penetration [9] and intraocular bioavailability of topically applied 
medications. BMT shows some adverse events iritis, hyperemia, macular edema and few 
cosmetic effects like (iris hyperpigmentation and eyelash growth) [6]. Howsoever to prolonged 
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exposure to benzalkonium chloride (BAK) in BMT drops has shown significant toxicity against 
both corneal and conjunctival cells. BAK containing medications are associated with increased 
tearing, burning, itching, and their long-term application may result in dry eye syndrome [10]. 
Poor adherence to daily dosing instructions for eye drop medication is usually observed in 
patients suffering from chronic ocular diseases. The compliance is lowest in old patients, who 
have difficulty with routine daily applications. However regular application is necessary in 
glaucoma, permanent lowering of IOP and a failure to sick to therapy, increases risk of 
developing blindness [11, 12]. Approximately half of the individuals who fill the glaucoma 
prescription discontinue all therapy within 6 months [13]. It was also found that 51% of patients, 
failed to get their prescription filled regularly in proper compliance with treatment as prescribed. 
Similarly 24% patients admitted to omitting eye drops either occasionally or frequently [14]. 
Furthermore, involuntary noncompliance is caused by the inability of the patient to place drops 
in the eye appropriately, leading to insufficient delivery of drug in as many as 20% of patients 
[15].  
A favorable way of addressing poor compliance and variations/ fluctuations in IOP is the use of 
sustained-release systems, which maintain therapeutic drug concentrations over a prolonged time 
while minimizing systemic losses due to absorption through the nasal mucosa. Continuous drug 
release may overcome the need for daily drug administration and hence would be more 
economical than daily application of eye drops, since smaller amounts of drug would now 
achieve similar or better effect. Employing hydrogels, micelles, nanocrystals, biodegradable 
nanoparticles, and dendrimers have been reported to decrease the frequency of drop 
administration [16-18]. Similarly transitioning from ocular drops that need to be administered 
once a day to a drop that needs to be given once after 2-3 days could also positively impact 
patient adherence, but may not completely manage the issue of poor patient compliance [16]. 
Injections and implants release drugs within the eye and may extend the release of drug up to 
several weeks or months [2, 19-22]. Biodegradable implants viz. Ozurdex
®
 available in the 
market are successful, however a surgical procedure or a special device is required to implant 
these into the eyes [23]. In situ gelling mucoadhesive formulations are also popular. These are 
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applied as simple eye drops forming a semi-solid gel as soon as they come in contact with the 
ocular surface. The gel should form a homogeneous layer on the corneal surface exhibiting 
pseudoplastic behavior during blinking to avoid patient discomfort and blurred vision while 
facilitating drug diffusion [24]. To be effective as a biomedical material, the transition 
temperature should be in the range of 10–40 ◦C. Some liquid crystal colloidal systems are also 
finding use in sustained delivery of drugs [25].  
To increase the convenience of administration and improve patient compliance, development of 
injectable drug delivery systems using conventional syringes instead of any sophisticated devices 
is still desired. The patient acceptance for such alternate therapies instead of eye drops was 
evaluated by administering a questionnaire to 151 patients with glaucoma. When questioned if 
they would trade their daily anti-glaucoma eye drops for a hypothetical alternate treatment mode 
like a 3-monthly subconjunctival injection, 74.4 % patients conveyed their preference for such an 
injection. Subconjunctival administration is well tolerated, safe, and used routinely in clinics for 
the delivery of various medications [26]. Safety of subconjunctival injection of bevacizumab for 
dry eye disease has been reported [27, 28]. A sustained drug release for up to 4 weeks has been 
shown with a subconjunctival implantation of bimatoprost (BMT) loaded natural polymer disks 
in rat eyes [29].  
Presently, we loaded BMT in a surfactant-based novel (IPA/700/DEL/2014) nanovesicular (NV) 
system which was further incorporated into in-situ gelling drops or implant (GEL-IM) formula, 
comprising thermosensitive polymers viz. poloxamer 407 and carbopol 934P to manage any 
burst release of unencapsulated BMT or that present on the surface and achieve prolonged 
release for more than a month. The developed BMT-NV-GEL was evaluated extensively for i) 
particle size, zeta potential, size distribution and morphology; ii) rheology; iii) drug 
incorporation and compatibility with additives (DSC and FTIR); iv) stability; v) three tier: in 
vitro, ex-vivo and in vivo safety; vi) sustained IOP lowering effect following application as 
drops or as subconjunctival implant/injection and comparison of the efficacy with marketed 
drops of BMT in an animal model of glaucoma.  
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2. MATERIALS AND METHODS 
2.1. Materials 
Bimatoprost (BMT) was a kind gift from FDC Ltd., Mumbai, India and poloxamer 407(P407) 
was gifted by Ranbaxy Pvt. Ltd., New Delhi, India. Acetonitrile (ACN) and methanol (HPLC 
grade) manufactured by Merck-Schuchardt, Hohenbrunn, Germany, were purchased from local 
vendors. HPLC grade water was produced by a Milli-DI system by Millipore (Billerica, 
Massachusetts, USA). Syringe filters were purchased from Waters India Pvt Ltd. All other 
reagents used in the study were of analytical grade. 
2.1.1.  Preparation of BMT loaded nanovesicles (BMT-NVs) and gel (BMT-NV-GEL) 
2.1.1.1. BM-NVs 
BMT-NVs were prepared by a modification of the ethanol-injection technique. The system was 
novel in terms of composition and method of preparation (IPA/700/DEL/2014). Span 60 and 
BMT (0.03%) were dissolved in defined quantity of hot ethanol to form the organic phase. PEG 
400 was dissolved in water and heated to 78-80
o
C (boiling point of ethanol) to form the aqueous 
phase. The organic phase was added in a thin but continuous stream, to the aqueous phase under 
continuous stirring at 1500 rpm using a mechanical stirrer (Fig.1). The stirring was continued till 
volume of the mixture was reduced to the original volume of the aqueous phase, ensuring 
complete removal of ethanol from the final formulation. BMT-NVs were obtained as an aqueous 
dispersion of BMT loaded NVs and was used as such without removing unencapsulated BMT 
(Fig. 1). 
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Fig. 1: Diagrammatic representation of BMT nanovesicular system fabrication, gelling on instillation into 
rat eye and drug release. 
  
2.1.1.2. Ethanol residue in BMT-NVs is described in supplementary data 
2.1.1.3. Preparation of BMT-NV loaded gel (BMT-NV-GEL) 
BMT-NV-GEL was prepared using cold method. Required quantity of gelling polymers were 
added in cold water and/or in BMT-NV dispersion and kept at 4°C with periodical stirring to 
ensure complete dissolution. Various combinations of viscosity enhancing polymers were 
tried in combination with P407 as described in table 1.  
Note: Fluorescein sodium (0.3% w/v) loaded NV-GEL (F-GEL) were also prepared similarly 
except that BMT was replaced with fluorescein sodium.  
BMT solution (BMT-SOL) 0.3% was used as a control for BMT-NV-GEL. 
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2.2. Characterization 
BMT-NV were characterized for particle size, zeta potential, total drug content (TDC), 
entrapment efficiency (EE), in vitro release, transmission electron microscopy (TEM) and optical 
microscopy. 
BMT-NV-GEL was extensively evaluated for particle size, zeta potential, TDC, DSC, FTIR, 
rheology, in vitro release and optical microscopy. 
Details of the employed methods are elaborated below. 
2.3. Morphological analysis, size and zeta potential 
BMT-NV and BMT-NV-GEL were observed after suitable dilution (10X) with distilled water 
under optical microscope (Nikon eclipse i90, Japan). BMT-NVs stained using 2% 
phosphotungstic acid (PTA) dissolved in pH 6.8, phosphate buffer, for 5 min, were spread on a 
carbon coated copper grid and examined under TEM (80 kV, model H 100, Hitachi Ltd., Japan). 
Morphological parameters like size, sphericity and aggregation were noted.    
2.3.1. Particle size and zeta potential 
Mean diameter and PDI of BMT-NV dispersion and BMT-NV-GEL (10x dilution) was 
determined using photon correlation spectroscopy (Delsa™ Nano C, Beckman Coulter, USA). 
Zeta potential of the samples were measured using Delsa™ Nano C, Beckman Coulter) at 25 ºC 
and the electric field strength of 23.2 V/cm. 
2.3.2. Quantification of BMT (TDC and EE) 
BMT concentration in BMT-NV and BMT-NV-GEL-IM was confirmed using high performance 
liquid chromatography (HPLC) method. A Waters HPLC equipped with a Waters e-2695 
ALLIANCE separation module comprising of 717 auto injector, a degasser module and a 2996 
PDA detector was used. Waters column, Symmetry RP-18 (4.6 mm x 250 mm) with a particle 
size of 5 mm, was used for the stationary phase at room temperature. Data acquisition was 
performed by the Empower2
®
 software and the detection of BMT was carried out at ʎmax of 210 
nm. Mobile phase comprised of a mixture of 10mM ammonium acetate buffer: acetonitrile (45: 
55) at a flow rate of 1.0 mL/min with injection volume 10 µl. Before analysis, mobile phase was 
filtered through 0.2 μm nylon membrane filter and degassed using sonication. All analytical 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
9 
 
 
samples were also filtered through 0.2 μm nylon membrane filters before injecting into the 
column. Analysis was performed at column temperature of 30°C while the samples were 
maintained at a temperature of 25°C. Samples were dissolved in isopropyl:ethanol (50:50) and 
all solvents used were of HPLC grade (Merck-Schuchardt, Hohenbrunn, Germany). The method 
was validated for accuracy, precision, LOD and LOQ in accordance with ICH guidelines. Limit 
of detection (LOD) and quantification (LOQ) were determined at signal to noise ratio of 3:1 and 
10:1 respectively. 
BMT-NV and BMT-NV-GEL dispersions (0.5 ml) were disrupted using an appropriate quantity 
of a mixture of isopropyl alcohol: water (1:1) till a clear solution was obtained and the solution 
was filtered (0.45 µ) and suitably analyzed for BMT content using previously described and 
validated HPLC method. 
The EE was determined by dialyzing BMT-NV dispersion (0.5 ml) in a dialysis bag (7k Da MW 
cut off) immersed in 75 ml water and stirred magnetically. After 60 min formulation was 
removed from the bag, disrupted with suitable quantity of isopropyl alcohol:water (1:1) and 
amount of drug was determined spectrophotometrically using HPLC. Mass balance was 
confirmed by measuring the quantity of BMT in the dialysate. 
Both TDC and EE was determined for six different batches prepared separately to confirm 
reproducibility of the developed method. 
2.4. DSC and FTIR 
Samples (2-5 mg) of pure drug (BMT); various components viz. span 60, PEG 400, P407, 
carbopol 934P and BMT-NV-GEL and corresponding blank gel were scanned using DSC (821e 
Mettler Toledo, Switzerland). Thermograms were observed for shifts in peaks and/or 
disappearance/appearance of new peaks. Indium (m.p. 156.6 ºC and H of 25.45 J gm
−1
) was used 
for calibrating the DSC for temperature and heat flow accuracy. The DSC was run from 0 to 300 
ºC at a rate of 10 ºC/min. Nitrogen gas was used at a purging rate of 50 ml/min.    
Similarly FT-IR spectra of all the above samples were also obtained over a range of 400- 4000 
cm
-1
, using FT-IR spectrometer (Agilent Technologies 630 Cary) and Micro Lab software.  
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2.5. Determination of sol–gel transition temperature 
The sol–gel transition of combination of P407 with various viscolysing polymers was determined 
by inverting the test tube at 180
o
 at increasing temperatures of 1
o
C step size [30]. The vials with 
0.5 ml formulation were immersed for 1 min, in a water bath at each temperature, and 
observations were made. Temperature, at which there was no visible flow within 30s of 
inversion, was the sol-gel transition temperature. 
2.6. Rheology is described in supplementary data 
2.7. In vitro release 
In vitro release of drug from 0.5 ml BMT-NV and BMT-NV-GEL were performed across the 
presoaked (for 12h in deionized water) dialysis membrane (cut off 7 kDa MW) mounted between 
the donor and the acceptor compartments of a modified Franz diffusion cell. Simulated tear fluid 
of pH 7.2 was used as the receptor fluid (20 ±2 ml), maintained at 37±0.5ºC and stirred at 50 
rpm. The procedure was repeated for BMT-SOL at similar concentration and under similar 
conditions. Aliquots of the receptor medium were withdrawn at suitable time intervals and were 
replaced with an equal volume of fresh medium to maintain the sink conditions. Withdrawn 
samples were suitably diluted and analyzed using HPLC.  
2.8. Stability study 
BMT-NV-GEL was stored in tightly closed, screw capped vials, at 2-8 ºC and at 37 ºC for 6 and 
3 month respectively. Samples were withdrawn periodically and analyzed for particle size, total 
drug content and in-situ gelling behavior.  
2.9. Sterilization and sterility testing 
BMT-NV and BMT-NV-GEL were sterilized by autoclaving at 121ºC (15 psi pressure) for 20 
min. Any change in terms of TDC, particle size and % entrapment, leakiness (in case of BMT-
NV) was noted post sterilization. Sterility testing studies were performed in order to ensure the 
sterility of finished autoclaved product following direct inoculation method [31]. Sample (1 ml) 
was drawn aseptically from the containers and transferred to fluid thioglycollate medium (50 ml) 
and soybean-casein digest medium (50 ml), respectively. The medium was incubated for 14 days 
at 30 °C-35 °C in case of fluid thioglycolate medium and 20 °C-25 °C in case of soybean-casein 
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digest medium and was observed for growth every day. Suitable negative and positive controls 
(Bacillus subtilis for fluid thioglycolate and Candida albicans for soybean-casein digest 
medium) were included in the test to confirm sterility and growth potential of the media 
employed respectively.  
2.10. Establishing safety of the developed system is described in data in brief [32] 
2.11. Pharmacodynamic evaluation 
2.11.1. Induction of glaucoma and grouping of animals 
Male Wistar rats, not more than 250 g, bred in the Central Animal House, Panjab University, 
Chandigarh, India, were used. Animals caged together in groups of seven were kept under 
natural light/dark cycle, were given food and water ad libitum. The experimental protocol was 
approved by the Institutional Animal Ethics Committee (PU/IAEC/S/16/110, dated11/7/2016), 
Panjab University, Chandigarh, India. The baseline IOP was measured twice daily using a 
caliberated Schiotz A Tonometer (Riester) for 7 days in all the rats. The animals having average 
IOP between 14.0-16.5 mmHg were selected for the study (Fig. 2). Animals were divided into 
seven groups: each consisting of six animals. Group I (Naive Control) consisted of animals 
receiving no treatment and served as negative control. Gp II to Gp VII  animals received 0.1% 
dexamethasone eye drops (DEX drops) 4 times a day for up to 4 weeks [33] at the same time 
each day. Elevation in IOP was noticed after 8 days of dosing and more than double IOP value 
was observed with respect to the baseline IOP in about 80% of the treated rats at the end of third 
week. It is reported that the elevated IOP returns to normal within a week of discontinuing DEX 
administration [34]. Further, since the developed implant was expected to show its efficacy at 
least for 2-3 months hence it was considered important to maintain the raised IOP throughout the 
study period by continued administration of DEX drops. However from the fourth week 
onwards, the dosing was reduced to two times a day, after confirming that the elevated IOP was 
maintained at this dosing pattern.  Hence Gp II to Gp VII animals were exposed to DEX two 
times a day for the remaining study period. It was confirmed that there was no significant 
difference in IOP of rats of various groups (p=0.05) at the start of treatment. Gp II served as the 
positive control group (receiving no treatment), Group III animals received marketed drops 
(Lumigan 0.03%) daily administration, Gp IV and V (vehicle control) received subconjunctival 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
12 
 
 
injection (100 µl) or a drop (30 µl) of Blank- NV-GEL respectively. Gp VI (BMT-NV-GEL-IM) 
received subconjunctival injection (a total of 100 µl) at two different sites. Procedure for 
subconjunctival injection was performed under topical anesthesia (paracaine 0.5%). GpVII 
received single administration of BMT-NV-GEL drop (30 µl). IOP was measured at different 
time points viz. 2, 4, 6, 12 and 24 h and after that daily at the same time (to correct the diurnal 
variations) till the time when IOP returned to baseline. Visual inspection of all eyes for clinical 
signs of inflammation in the eye and at the injection site and for any evidence of infection was 
done prior to injections and daily thereafter for one week. We used a modified version of the 
Moorfields bleb grading system to objectively assess vascularity in all eyes [35]. 
 
Fig.2: In vivo experiment design of pharmacodynamics study. 
2.12. Proof-of- concept studies 
2.12.1. Cellular uptake in corneal (HCLE) and conjunctival (HCjE) cell lines 
Stratified human corneal and conjunctival epithelial cells grown on 24-well cell culture plates 
were incubated with F-GEL (NV-GEL loaded with fluorescein sodium 0.3% w/v) or with 
fluorescein sodium solution 0.3% w/v (F-SOL), both diluted (1:20) in serum-free DMEM/F12 
for 3 h at 37 ºC. After incubation, the medium was aspirated and the cell cultures washed three 
times with ice-cold PBS. The cells were then solubilized in 0.1 M NaOH/5% SDS, and the cell 
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lysates from each well used to quantify fluorescence using a Fluoroskan Ascent FL (Thermo 
Fisher Scientific, Rockford, IL). 
2.12.2. Confocal microscope studies 
Fluorescein tagged BMT-NV-GEL (100 μl) was injected subconjunctivaly in to the right eye of 
rats. Animals were sacrificed at 15
th
day, 1 month and 2 month post injection of the formulation. 
Eyes were enucleated immediately and stored at -20 °C. The eyes were embedded in 
cryomatrix
TM
 before sectioning, and the samples were sliced into 10 μm thick sections using a 
cryostat (IEC Minotome 3398, American Instrument Exchange, Inc., Massachusetts, USA). 
Sections were then fixed onto slides. The complete eye sections were observed using confocal 
laser scanning microscope (Nikon Eclips Ti, NIS Element, Japan) using a 63 oil immersion 
objective and an aperture of 1 Airy unit. All protocols were approved by the animal ethics 
committee (IAEC) of Panjab University, Chandigarh (PU/IAEC/S/16/110, dated11/7/2016). Stay 
of fluorescein tagged BMT loaded in-situ gel system was also studied when applied as ocular 
drops and the eyes were enucleated one week post administration. 
2.13. Statistical analysis 
All results are expressed as the mean±standard deviation. The results were analyzed for 
statistical significance by a one-way analysis of variance (ANOVA) test followed by the Tukey’s 
test or the Students pair t test, whichever applicable. 
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3. RESULTS AND DISCUSSION 
3.1. Preparation of BMT-NVs and BMT-NV-GEL 
Biodegradability, biocompatibility, low immunogenicity and antibacterial activity are some 
properties being looked into for successful use of polymers in drug delivery. A variety of food-
grade protein and polysaccharide based biopolymers, including whey proteins, casein, soy 
proteins, gelatin, zein, starch, cellulose, and various other hydrocolloids can be used to fabricate 
controlled release systems [36]. Various biopolymer drug delivery systems including hydrogels, 
nanoparticles, and nanogels are presently being opted as suitable carrier strategies. 
Presently we employ an in situ gel-forming ophthalmic drug delivery system both as an implant 
and as ocular drops. Such system employs polymers that exhibit reversible phase transitions 
(sol–gel) and pseudoplastic behavior to (i) minimize interference with blinking and (ii) extend 
residence time and act as a controlled release system. Stimuli-responsive or ‘smart’ polymers are 
macromolecules that display a significant physiochemical change in response to small changes in 
their environment [37]. The signs or stimuli that trigger the structural changes on smart polymers 
can be classified in three main groups: physical (temperature, ultrasound, light or mechanical 
stress), chemical (pH and ionic strength) and biological (enzymes and other biomolecules). 
Presently employed polymers were sensitive to temperature and change their microstructural 
features at physiological temperature. These are the most studied, used and safe polymers in drug 
administration systems [38]. 
Poloxamer (poly (ethylene oxide)–poly (propylene oxide)–poly (ethylene oxide) (PEO–PPO–
PEO), a thermosenstive amphiphilic block copolymer, has been explored extensively as an in-
situ gelling system [39, 40]. Thermogelling of poloxamers is described by the interaction of 
different segments of the copolymer with each other. The poloxamer copolymers aggregate into 
spherical micelles, with a dehydrated core  of polyoxypropylene (PPO) and the outer shell of 
hydrated swollen polyoxyethylene (PEO) chains [41]. With increase in temperature, dehydration 
and conformational changes occur at the hydrophobic chain regions, resulting to an increased 
chain friction and formation of a polymeric meshwork [39]. This results in availability of larger 
unbound water in the hydrophilic regions of the gel such that the outer PEO chains interpenetrate 
within the interior of the gel. The gelation is affected with the micelles remaining intact and 
packed orderly in a condition described in literature as the ‘‘hard-sphere crystallization” [42]. 
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Though widely employed as gelling agents poloxamers are limited by their weak mechanical 
strength, which can result in rapid erosion [43]. Hence, we presently used a blend of poloxamer 
[40] and other polymers like carbopol 934 P [30, 44], HPMC [45], CMC [42], poloxamer 188  
and chitosan [46] (Table 1). P407 showed a suitable in-situ gelling behavior between 37.5-39
o
C 
when used alone at 20% w/v concentration [42]. However when mixed with vesicles the gelling 
temperature increased to ≥38 oC. Latter was probably due to the traces of ethanol present in the 
NV dispersion [39]. A blend of P407 with carbopol 934P (F12-F16; Table 1) showed a good in-
situ gelling behavior at 37±0.5
o
C. Carbopol, a mucoadhesive polymer not only increases the 
mechanical strength of the formulation but also shows improved surface contact with the ocular 
tissues [30].  The formulation F 16 was selected as the best suitable option. 
An impressive number of novel temperature-sensitive poloxamer based in situ forming system 
have been reported for sustained ophthalmic drug delivery  but none of them can sustain the 
therapeutic effect of enclosed drug to more than two weeks. Thus, a combination of two drug 
delivery systems, i.e., NV and an in-situ gelling system (Fig. 1), were employed presently to 
achieve sustained therapeutic effects beyond weeks to months. Bimatoprost was incorporated 
into novel (IPA/700/DEL/2014) nanovesicular system which was then gelled employing an in-
situ gelling system.  
Vesicular drug delivery systems are gaining great acceptance in drug delivery.  However, these 
conventional systems are usually phopholipid based which although a versatile component is 
prone to oxidation and hydrolysis leading to compromised stability of the system [47]. The 
former combined with other natural ingredients, like cholesterol, of conventional vesicular 
systems result in decreased stability, high cost, drug leakiness and at times poor reproducibility 
and a batch-to-batch variation. Furthermore, the used methods of preparation like thin film 
evaporation, reverse phase evaporation, ethanol/ether injection and/or use of homogenisation or 
ultrasound technology, are suited to laboratory scale production [48]. Large scale industrial 
manufacturing process of uniform, reproducible, well-characterized, and stable vesicular 
formulation(s) essential for the commercial success of any delivery system [49] is yet to be 
developed. This could be the reason why these systems did not find a more wide spread 
applicability and market.  
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In view of above, efforts of the present work were centered on devising a simple and optimized 
vesicular system, which is novel (IPA/700/DEL/2014) both in terms of composition and its 
method of preparation. The target was to define a cost effective, reproducible, and a scalable 
system which can effectively encapsulate the drug with minimal leakage. Synthetic components 
were selected, such that issues related to stability and purity of raw material with no batch to 
batch variation, were addressed. Another, intent of the study was to develop an effortless, simple 
technique of manufacture conducive to industrial scale up. The hydrophobic bilayer and small 
size were two other aspects focussed on. 
 
 
 
 
 
 
Table 1: Optimization of BMT-NV loaded in-situ gelling system.  
F. Code P407 (%) Other 
Polymer 
(% w/v) 
Other Polymer 
(% w/v) 
Vesicle+ 
Water 
In-situ gelling temp/comment 
F-1 26 - - 5+5 In-situ gelling temperature was found 
at 28
 o
C-30
o
C. 
F-2 20 - - 0+10 In-situ gelling temperature was found 
between 37.5-39
o
C 
F-3 20 - - 5+5 In-situ gelling temperature was found 
between 38-39.5
o
C. 
The increase in gelling temperature (F-
2) may be due to presence of traces of 
ethanol in vesicular system. 
F-4 16 P 188 (14) - 5+5 In-situ gelling temperature was found 
at 50 
o
C 
F-5 20 Na CMC 
(3) 
- 5+5 Very thick and uneven gel was formed 
on storage at 4
o
C. In-situ gelling 
behavior was absent. 
F-6 20 Na CMC 
(3) 
- 5+5 Uniformity and in-situ gelling behavior 
was absent. 
F-7 20 HPMCK4
M (1.5) 
- 5+5 Not gelled even at 50
o
C. 
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F-8 20 HPMCK15 
(1.5) 
- 0+10 Found in-situ gelling behavior at 37
o
C 
and very quick reversibility. 
F-9 20 HPMCK15
M (1.5) 
- 5+5 Freely flowing at 37
o
C and not gelled 
even at 48
o
C. 
F-10 16 P 188 (14) Chitosan (1) 
dissolved in in 
0.01M glacial 
acetic acid 
5+5 Chitosan got precipitated after mixing 
all three and storage at 4
o
C. 
F-11 16 P 188 (14) Chitosan (1) 
dissolved in in 
3% citric acid 
5+5 Very good sol form at 4
o
C but not 
gelled even at 45
o
C. 
F-12 16 Carbopol 
934P (3) 
- 5+5 Showed in-situ gelling behavior at 37-
38.5
o
C but syringeability was not so 
good. 
F-13 16 Carbopol 
934P (1) 
- 5+5 Showed in-situ gelling behavior at 33-
35
o
 and improved syringeability. 
F-14 14 Carbopol 
934P (1) 
- 5+5 Showed in-situ gelling behavior at 36-
37
o
C and very good syringeability. 
F-15 12 Carbopol 
934P (1) 
- 5+5 Showed in-situ gelling behavior at 
37
o
C±0.5
o
C and very good 
syringeability and reversibility. 
F-16 12 Carbopol 
934P (1) 
- 10+0 Showed in-situ gelling behavior at 
37
o
C±0.5
o
C and very good 
syringeability and reversibility. 
HPMCK15M and HPMCK4M are hydroxyl propyl methyl cellulose of grade K15M and K4M 
Several blank batches were initially prepared by varying the concentration of span 60 and PEG 
400 (Table 2). Formulation F1 was selected based on smaller size, which changed minimally 
following sterilization by autoclaving. Since BMT is sufficiently soluble in water and highly 
soluble in ethanol hence it was tried to load BMT both in water as well as the organic phase.  
Entrapment efficiency was remarkably high when BMT was added to the organic phase (76.4% 
in comparison to 64% when loaded in aqueous phase). The unentrapped (~24%) BMT was not 
removed as its release will be sustained by the use of P407–carbopol gelling system.  
 
Table 2: Various NV compositions used for optimization. 
Formulation Span 60 
(%) 
PEG400 
(%) 
TDC (EE) 
(%) 
Particle size 
(nm) 
After autoclave 
particle size (nm) 
F1 0.40 4.44 - 161.7 176.5 
F2 0.80 11.2 - 182.1 284.3 
F3 0.80 4.44 - 185.7 198.2 
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F1-DL (organic phase) - when drug D (bimatoprost) was incorporated in the organic phase during 
preparation of NV 
F1-DL (aqueous phase) - when drug D (bimatoprost) was incorporated in the aqueous phase during 
preparation of NV 
 
Results of gas chromatography of BMT-NV (Supplementary Fig. S1 and Supplementary Table 
S1) showed a peak corresponding to ethanol which is a class 3 solvent and is considered to be 
safe at or below 5000 ppm (0.5%) concentration in pharmaceutical formulations as residual 
solvent [50]. Comparing the AUC of 5000 ppm ethanol and the peak shown by BMT-NV 
corresponding to ethanol (RT 2.35 and 2.33 respectively),  it can be concluded that amount of 
residual   ethanol in the BMT-NV is sufficiently below (  40%) the allowed limit of 5000 ppm 
which will  be further lowered by addition of polymers in the final BMT-NV-GEL formulation. 
USFDA approves the limit of ethanol in an ophthalmic solution as 1.43% [51]. 
 
3.2. Characterization 
3.2.1. Morphological analysis. 
 
 
F4 0.40 11.2 - 180.5 198.4 
F1-DL 
(organic phase)  
0.40 4.44 92.3 (76.4) 160.9 169.2 
F1-DL 
(aqueous phase)  
0.40 4.44 93.2 (64.0) 165.2 177.4 
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Fig. 3: TEM micrographs of BMT-NV at a) 30000x, b) 100000x magnification 
Red arrows indicate bilamellar NVs  
 
Both optical microscopic (Supplementary Fig. S2) and TEM images of the BMT-NV (Fig. 3) 
indicated their small size, round, unilamellar/bilamellar structure with no aggregation or 
irregularities. Furthermore their hollow, central core enclosed by bilamellar structure, confirmed 
their vesicular characteristics. A dark outer lining/surface observed around the vesicles is the 
PEG coating, which will assign a i) suitable rigidity to the vesicles ensuring their stability [52]  
even following autoclaving;  and ii) Pgp efflux inhibition capacity, coupled with the capacity to 
bypass reticulo-endothelial system (RES) pickup of the developed vesicles. Incorporation of  
PEG in the normal architecture of these vesicles is a better option than the  PEGylated systems 
where PEG is attached on the surface either by surface adsorption or covalent binding [53]. 
Latter not only involves a separate manufacturing step but may also increase the size of resulting 
vesicles and can be removed on dilution. 
Further, microscopic images of BMT-NV-GEL clearly indicated uniformly distributed vesicles 
embedded in gel network (Supplementary Fig. S3).  
 
3.3. Particle size and zeta potential 
The developed BMT-NV showed an average particle size (n=6) of 165.7 ±10.5nm and PDI of 
0.147±0.02 (n=6). The PDI <0.2 indicates narrow particle size distribution. Small size offers a 
greater surface area for association with conjunctiva, thus resulting in higher permeation of intact 
vesicles [54]. Retention and ocular distribution of subconjunctivaly administered nanoparticles 
of varying size (20 nm and 2000 nm) and of microparticles (2 µm) [55] indicated that very small 
particles (20 nm) undergo rapid clearance from the periocular tissue as compared to the larger 
particles (200 nm and 2 µm) which are retained for periods  as long as two months. Systemic 
clearance via periocular blood or lymphatic circulation was indicated as a probable reason for 
rapid clearance of small particles when administered subconjunctivaly [56]. However particles ≥ 
200nm could not cross the various ocular barriers, indicating particles >20 nm and <200 nm to 
be of a favorable size for greater ocular uptake. Particle size distribution of presently prepared 
and reported formulation (Supplementary Fig. S4a) shows that none of the particle is less than 63 
nm or in micron size. Majority (80 %) of the particles were found to lie in the range of 60 -257 
nm hence the achieved particle size is expected to show favorable periocular and subconjunctival 
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retention and uptake. Furthermore incorporation of BMT-NV into an in-situ gelling system 
(average particle size 810±12.3 nm) confirms their enhanced retention for longer time 
(Supplementary Fig. S4b).   
Zeta potential of BMT-NV was -46.39 mV while that of BMT-NV-GEL was -4.67 mV. A zeta 
of ≥ 25 mV imparts stability to aggregation. Formation of binary mixture of ethanol-water (when 
organic and water phase are mixed) was considered responsible for the presently observed  
negative zeta potential [57].  
3.4. Quantification of BMT 
The calibration curve of BMT in ethanol:water (50:50) was found to be linear at the tested 
concentration range of 1.0 to 50.0 μg/ ml, with r2 value of 0.999. The method was validated in 
terms of inter-day and intra-day variation and the % RSD value was found to vary between 1.87 
to 2.62 and 1.01 to 2.67%, respectively (Supplementary Table S2) upon repetitive determinations 
(n=3, in both case) which proves the fitness of the developed method as per ICH guideline 
(precision ≤ 3). The limit of detection (LOD) and quantification (LOQ) determined at signal to 
noise ratio 3:1 (LOD) and 10:1 (LOQ) was 0.2μg/ml and 0.4μg/ml respectively. 
 
Standard plot of BMT was also prepared in isopropyl alcohol: water (50:50) for determination of 
TDC and EE by HPLC. A linear correlation was obtained (r
2
= 0.999, n=3) at the tested range (1-
50 µg/ml). 
 
3.5. Total drug content (TDC) and entrapment efficiency (EE) 
The drug content of the developed BMT–NV was 2.81±0.05 mg/ml which was 93.34±1.21% of 
what was originally incorporated (3mg/ml) and the entrapment efficiency was 76.8±1.52% 
(n=6). Incorporation of BMT-NV into in-situ gelling formula resulted in TDC of the final 
formulation (BMT-NV-GEL) of 2.70±0.04 mg/ml (90% of initially incorporated BMT 
concentration).  
3.6. DSC and FTIR 
The DSC spectra for BMT, span 60, PEG 400, P407, carbopol 934P, Blank -NV-GEL and BMT-
NV-GEL are shown in fig. 4a. Melting endotherm of BMT, corresponding to its melting point 
appeared at 71.48 °C with an enthalpy of 79.30 J/g.  P407 showed a sharp peak at 57.29 °C with 
enthalpy 166.1 J/g and an endotherm at 50.68 °C (65.53 J/g) was observed for span 60. Carbopol 
934P showed broad endotherms at 77.42 °C and 185.11 °C which disappeared in the blank-NV 
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loaded gel and BMT-NV-GEL, indicating carbopol skelton probably intertwine P407 gelling 
network. A somewhat sharp endotherm corresponding to span 60 at 50.48°C with a significantly 
low enthalpy observed for blank (7.05 J/g) and BMT loaded NV-gel (41.54 J/g) indicate a stable 
nanosystem with efficient incorporation of BMT in to the NV. A higher enthalpy observed for 
BMT-NV gel (41.54 J/g) versus blank gel (7.05 J/g) may be attributed to incorporation of 
unentrapped BMT and PEG 400 into the in-situ gelling network.  
The FTIR spectra for BMT, Blank -NV-GEL, BMT-NV-GEL and all other excipient are shown 
in fig. 4b. Free BMT showed intense absorption bands at 3311 cm
−1
 (O-H stretch), 3430 cm
−1 
(N-H stretch), 3078 cm
−1
 (aromatic C-H stretch), 2932 cm
−1
 (aliphatic C-H stretch) 1641 cm
−1
 
(C=O stretching of amide), 1549 cm
−1
 (C=C aromatic stretch) and1269 cm
−1
 (C-N stretching of 
amide), respectively. P407 exhibit characteristic peaks at 2882 cm
−1
 (alkane stretch), 1357 cm
−1
 
(In plane O-H blend) and 1109 cm
−1 
representing C-O bond stretch. Carbopol 934P showed 
intense absorbtion peaks at 2929cm
−1
(O-H stretch) and 1714.53cm
−1 
(carboxyl group stretch). 
Presence of characterstics peaks corresponding to P407 (2880 cm
-1
, 1354 cm
-1
,1109.24 cm
-1
and 
842 cm
-1
) and carbopol 934 P (1714.53cm
−1
; carboxyl group  which is shifted to somewhat 
higher wavelength i.e 1731 cm
-1
) was observed both for Blank-NV and  BMT-NV-loaded gel. 
This observation indicates that Carbopol 934P intertwine with P407 gel network.  
The similarity of the FTIR spectra obtained for BMT-NV-GEL to that exhibited by blank-NV- 
GEL and absence of specific peak corresponding to BMT in the former, confirms efficient 
encapsulation of BMT within the vesicular system. Although entrapment efficiency obtained by 
the analytical procedure is 76.8% w/v, it may be said that the unentrapped free drug (~ 24%) is 
also entrapped with in the in-situ gelling network of P407 and carbopol 934P, so that it is not 
identifiable as a separate unit by FTIR. 
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(a) 
 
(b) 
Fig. 4: DSC (a) and FTIR (b) spectra of BMT, BMT-NV-GEL, Blank-NV- GEL, and various components of 
BMT-NV-GEL. 
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3.7. Determination of sol–gel transition temperature 
Sol–gel transition temperature of the final formulation was found to be 37±0.5oC (n=6). Gelation 
of P407 takes place due to orientation of body centered cubic packaging of its spherical micelles 
at above critical micellar concentration (1 mg/ml). Temperature plays important role in the 
micelle formation of P407 through the temperature dependent hydration of ethylene oxide units. 
At lower temperature, water serves as good solvent for PEO and PPO units of P407 such that 
hydrogen bonding between PPO chains and water keeps hydrophobic portions of poloxamers 
separate. At higher temperature, hydrogen bonding is disrupted and hydrophobic interactions 
causing a gel to be formed. Thus, gelling properties of poloxamers are dependent on proportion 
of hydrophobic portion. It is reported and was also observed presently that P407 at the 
concentration of 18-20% gels between 37-38
o
C. Decrease in gelation temperature was observed 
with increase in P407 concentration due to increase in its hydrophobic portion [45]. To develop 
in-situ forming delivery system of BMT-NV using lower concentration of P407 (14%), it  was 
combined with other polymers viz. carbopol 934P, HPMC, P188 and CMC which are reported to 
exhibit reversible sol-gel phenomenon at lowered P407 concentration [39, 45]. Similar was 
observed presently on combining P407 with 1% carbopol 934P, when the required concentration 
of P407 reduced from 20% to 14%. Consistent properties were maintained when P407 
concentration was lowered from 14 to 12%. The gelation temperature of 14% aqueous solution 
of P407 alone is reported to lie between 43-45 
o
C [46, 58]. Addition of carbopol 934P resulted in 
the formation of hydrogen bonding with ethereal oxygen of P407, resulting in a decreased 
gelation temperature. A progressive decrease in sol-gel transition temperatures with increase in 
carbopol 934P concentrations was observed. Similar is also reported in earlier studies [43]. 
Agents like ethanol, propylene glycol, and hydrochloric acid, which form weak hydrogen bonds, 
however tend to  increase gelation temperature [39]. Similar was noted when P407 was added 
directly into BMT-NV probably containing traces of ethanol.   
3.8. Rheology of BMT-NV-GEL is discussed in supplementary data 
3.9. In-vitro release 
 The drug release profile of BMT-NV and BMT-NV-GEL indicates biphasic release kinetics of 
BMT as shown in fig. 5. BMT showed a prolonged release with 93% drug release at 144 h (6 
days) from BMT-NV. BMT-NV-GEL showed an even better sustained effect with 51% drug 
release at 144 h and 80.23% at 240 h (10 days). However approximately 24% of the drug was 
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released initially within 2 h from BMT-NV. This corresponds to the unentrapped drug (  26.4%) 
concentration. The   slightly soluble nature of BMT and its partial incorporation in the outer PEG 
layer of vesicles could also be responsible for the initial release [59]. PEG has strong affinity for 
water phase hence drug incorporated in outer PEG layer is expected to be released fast. The 
initial phase of release was however substantially diminished in BMT-NV-GEL indicating that 
free BMT was now entrained within the P188 and carbopol 934P gel matrix. Both BMT-NV and 
BMT-NV-GEL showed first order drug release (r
2
=0.972 and 0.982) for the first 2 h, after which 
the release followed a zero order (r
2
=0.972 and 0.962) pattern indicating controlled release. Out 
of the various models, Higuchi release model (r
2
=0.986 and 0.952) was best fitted for both BMT-
NV and BMT-NV-GEL indicating that drug release occurs by diffusion. Further fitting of the 
data in the Korsmeyer-Peppas equation indicate that the mechanism of drug release was Fickian, 
as the diffusion exponent (n value) value was < 0.45 (0.224 and 0.293 for BMT-NV and BMT-NV-
GEL respectively).  
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Fig. 5: In vitro drug release of BMT-SOL, BMT-NV and BMT-NV-GEL in simulated tear fluid (pH 7.2) 
 
3.10. Stability study 
No significant change (p<0.001) in  TDC and particle size of BMT-NV-GEL was observed upon 
storage under refrigeration for 6 months and at 37±2
o
C for 3 months indicating their long term 
stability (Table 3 and Table 4). TDC of BMT-SOL (99.7±0.52) was however reduced by almost 
(8%) at 6 months under refrigerated conditions.  
Table 3: Stability study at 5±3
o
C (n=3) 
                                              % Change in parameters with time 
Time 
(months) 
                             BMT-NV-GEL BMT-SOL  
TDC  In-situ gelling 
property at 37
o
C 
Particle size    TDC 
1 0.63 ± 0.12 Maintained 1.04 ± 0.80  1.5±0.51 
3 1.02± 0.15 Maintained 1.92 ± 1.05  2.9±1.0 
6 1.74± 0.51 Maintained 3.1 ± 1.36   7.6±1.6 
 
Values were not significantly different from one another, at p<0.001 for BMT-NV-GEL 
Values were significantly different from one another, at p<0.001 for BMT-SOL 
Zero time values for BMT-NV-GEL; TDC (%) =90.5 ± 018; Particle size (nm) = 806± 10.5. 
Zero time TDC for BMT-SOL (%) =99.7±0.52 
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Table 4: Stability study at 37±2
o
C (n=3)  
                                              % Change in parameters with time 
Time 
(months) 
                             BMT-NV-GEL BMT-SOL 
TDC  In-situ gelling 
behavior at 37
o
C 
Particle size      TDC  
1 1.03 ± 0.12 Maintained 1.24 ± 0.860  1.5±0.51 
3 3.92± 0.18 Maintained 1.92 ± 1.05   7.9±1.0 
 
The BMT-NV-GEL was stable upto 3 months at 37 
o
C. Though the study can be taken as the 
accelerated stability data but 37 
o
C (instead of 40 
o
C) was selected to confirm that the particle 
would maintain their integrity upon subconjunctival injection and the drug will be released 
slowly therein following dilution with body fluids.  
3.11. Autoclavability 
The developed BMT-NV and BMT-NV-GEL were found to be stable on autoclaving with no 
significant change (p<0.05) in TDC, entrapment efficiency (determined for BMT-NV) and 
particle size (Table 5). Sterilization is an important consideration in the case of ocular delivery. 
Terminal sterilization is especially required in present case as we propose a preservative free unit 
dose prefilled package and/or vial to avoid damage usually observed with preservative like BAK. 
The selected components P407 and carbopol 934P of in-situ gelling formula are thermostable, 
change their performance with temperature and hence are harmonious to steam sterilization [60, 
61]. It is reported that carbomers are stable and may be heated at high temperatures of 104ºC for 
up to 2 hours without affecting their thickening efficiency. With an increase in temperature, 
many nonionic surfactants like tween 80 (65 °C, cloud point) become less hydrophilic [62].  An 
aqueous solution of these surfactants separates into two phases and becomes turbid at a certain 
temperature, which defines their cloud point. Dehydration of the emulsifier at temperatures 
above the cloud point may lead to a breakdown of the film around the oil droplets and 
consequently cause coalescence and destruction of the droplets [63]. Hence, the surfactant cloud 
point is an important consideration to determine the dispersion stability upon heat treatment 
(autoclaving). For example, using a surfactant with a comparatively high cloud point improved 
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the emulsion’s stability upon autoclaving viz. P407 (above 140oC), and PEG400 (above 100 ° C) 
[63] employed presently. Resistance to change upon autoclaving observed presently is thus 
attributed to the presence of PEG400 as an outer layer (can be seen in TEM picture) around the 
vesicles. PEG being a plasticizer, increases the rigidity of the system facilitating stability to 
autoclaving and resist gelation [64]. At temperatures above the gelation the micelles change their 
shape from spheres to prolates, thereby negating their ability to assemble in a cubic packing. 
This leads to the reformation of the low viscosity sol phase. Above the cloud point (>140
o
C), the 
micelles separate into their own coacervate phase in excess water. Since the autoclaving 
temperature is 121
o
C so latter is neither expected and was nor observed.  
 
Table 5: Parameters before and after autoclaving (n=3) 
                     BMT-NV       BMT-NV-GEL-IM BMT-SOL
*
 
Autoclaving  % TDC  EE (%) Particle 
size(nm) 
(PDI)     
% TDC Particle size 
(nm) 
( PDI)   
% TDC 
Before  91.65±1.21  76.17±0.64  160.9±5.47 
(0.142±0.02) 
90.23±1.15 820.9±7.12 
(0.312±0.05) 
99.7±0.21  
After  90.95±1.93  75.27±1.57  169.8±8.19  
(0.140±0.03) 
89.97±1.25 824.8±6.19 
(0.322±0.04)  
 93.95±1.91  
*Values before and after autoclaving were not significantly different from one another within the group at 
p<0.05 except BMT-SOL. 
 
3.12. Sterility testing 
The developed and autoclaved blank formulation did not show growth of fungus and bacteria till 
14 days and were found to be sterile. The positive control and validation test showed growth, 
confirming the suitability of media and absence of any inhibitory activity of the formulation.  
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3.13. Establishing the safety of the developed system is discussed under data in brief 
3.14. Pharmacodynamic evaluation  
The baseline IOP was 15.26 ± 1.3 mmHg for all animals used in the study and there was no 
significant difference between all the 7 groups (P= 0.05; n= 42). After induction of glaucoma the 
average IOP in animals of Gp II-V increased to 42.95 ± 1.96 which was maintained in Gp II 
animals throughout the study period.  A significantly higher mean reduction of IOP following 
single subconjunctival BMT-NV-GEL-IM (Gp V)) administration compared to daily instillation 
of topical marketed lumigan eye drop (Gp IV) was observed upto 30 days. Results for BMT-NV-
GEL-IM group were comparable to marketed drop group from 30-34
th
 day. Beyond 34
th
 day IOP 
reduction in GpV was lower (P=0.05) than Gp IV but reduction was significant (P=0.05) with 
respect to the positive control (Gp III) animals (Fig. 6). Plateau phase observed from 36 to 40
th
 
days indicates that the sustained action of BMT-NV-GEL-IM may extend even up to 2 months 
following single administration. 
Ideally a treatment for glaucoma should maintain therapeutic level for long periods following 
single application [65]. Novel drug delivery strategies can achieve this by controlled release 
that sustains drug levels at the target site. Some inserts of antiglaucoma medicine for such 
extended release are already in market. DuraSite® system containing BMT showed ocular 
bioavailability superior to the conventional eye drops. However these (AzaSite and Besivance) 
need to be administered daily [66]. Similarly a chitosan-based ocular insert for BMT is also 
reported, which showed an effectiveness for over a month following sub-conjunctival application 
[67]. NOVADUR polymeric system for the sustained release of BMT is also reported [68]. The 
implant displayed IOP lowering efficiency for about six months however in this study 0.03% 
BMT drops were administered in contralateral eye daily. This  may help in maintaining IOP of 
fellow eye [69]. 
Further the polymer used in the latter case is 250-300 times costlier than presently used 
components. Moreover a special applicator is recommended with this system. Intracameral 
administration of solid (polymeric) implant may also result in blurring of vision and irritation 
which is not expected with the presently developed in-situ gelling (semisolid viscous gel 
following administration) system of bimatoprost and its subconjunctival administration. 
Subconjunctival injection is a promising method for delivery of controlled release medications. 
The subconjunctiva is a potential space that underlies the epithelial and connective tissue layers 
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covering the sclera. Hence, it places the drug close to the external sclera. Further BMT has been 
reported to reduce IOP more profoundly by uveoscleral outflow pathway compared to trabecular 
meshwork outflow [9]. Hence subconjunctival administration of bimatoprost will result in better 
efficacy (injection closer to target site i.e. uveoscleral) and safety.   
We also considered topical administration of BMT-NV-GEL formulation as an in situ gelling 
system, and compared the obtained results with the daily administration of Lumigan 0.03% 
drops. A significantly higher reduction in IOP, extending for three days following single drop 
administration, was achieved in comparison to the daily administration of Lumigan 0.03% drops. 
Furthermore, statistically significant reduction in IOP was noted for about one week in 
comparison to positive control group. This extended duration of action can thus enhance patient 
compliance and improve treatment outcomes. The enhanced effect and duration may be due to 
mucopenetrating action of poloxamer as well as mucoadhesive effect of Carbopol 934P. The NV 
system itself also has the capacity to release therapeutic entity for up to one week as also 
observed in the in-vitro release study (Fig. 5).  
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Fig.6: In vivo IOP reduction recording of single subconjunctival injection (100 µl) (a) and single drop 
administration (30 µl) into the eye (b) of BMT-NV-GEL and its comparison with marketed (MKT) drops 
(Lumigan 0.03%) administered daily. 
 
3.15. Proof of concept 
3.15.1. Cellular uptake study 
Internalization of NV-GEL system was quantified by fluorometry. Significantly higher 
fluorescence was observed for F-GEL with respect to F-SOL in both type of cells i.e  HCLE and 
HCjE (26-fold and 27-fold relative to F-SOL, respectively) (Fig.7) establishing superiority of the 
developed system. 
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Fig. 7: Fluorescence intensity in HCLE and HCjE cells after incubation for 3h. Both values are significantly 
different from each other and with respect to control (p <0.05). 
 
A representative illustration of confocal microscopy, substantiates capacity of rat eye to retain 
the developed system even after 2 months of application following subconjunctival injection 
(Fig.8a). Similarly significant diffuse fluorescence in the whole eye even after one week 
following topical administration gives a direct evidence of sustained effect [70] of the developed 
system (Fig.8b). 
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Fig.8: Confocal images at different time points of BMT-NV-GEL subconjunctival injection (a) and after 
topical application (b). 
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4. CONCLUSIONS 
Glaucoma is a chronic ocular disease requiring lifelong medication once initiated. Daily once or 
twice administration of drops results in poor patient compliance especially in elderly persons 
above 60 years of age. Presently BMT nanovesicles loaded poloxamer based in-situ gelling 
implant was successfully produced.    
A successful incorporation of BMT–NV into gel was confirmed by DSC and FTIR spectra. 
Further a strong intertwines interaction between the P407 and Carbopol 934P was achieved and 
confirmed by FTIR spectra. The sustained release of BMT was proven by pharmacodynamic 
effects (IOP lowering) and in vitro release studies. Developed implant was able to sustain the 
release of BMT over 2 month with single subconjunctival injection. Furthermore single 
administration as topical drop effectively lowered the IOP for 7 days. These results may reveal a 
potential application of this new formulation in glaucoma management, in order to improve 
patient compliance by lowering the frequency of administration and enhancing the therapeutic 
effectiveness of glaucoma medical treatment. 
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Highlights 
 Bimatoprost (BMT) is a pharmacologically superior prostamide, as it lowers intraocular 
pressure (IOP) by dual pathways. 
 Presently BMT was encapsulated in a surfactant-based novel nanovesicular (NV) system 
with greater stability, low cost and ease of preparation vis a vis a liposomal system. 
 TEM images of the BMT-NV indicate small size (165.7 ±10.5 nm; n=6), round, 
unilamellar/bilamellar structures with no aggregation or irregularities and high 
encapsulation efficiency of 76.8±1.52% (n=6). 
 BMT-NV were incorporated into in-situ gelling drops (GEL) or implant (GEL-IM) to 
achieve sustained effects from a single application. 
 Sol–gel transition temperature of the final formulation was found to be 37±0.5oC (n=6). 
 BMT showed a prolonged release with 93% drug release at 144 h (6 days) from BMT-
NV. BMT-NV-GEL showed an even better sustained effect with 51% drug release at 144 
h and 80.23% at 240 h (10 days). 
 Single injection of BMT-NV-GEL-IM group compared to daily application of marketed 
drops for more than a month. 
 Developed formulation showed 26 to 27-fold improved permeation into corneal (HCLE) 
and conjunctival (HcjE) cells. 
 Confocal microscopy substantiated capacity of rat eye to retain the developed system for 
more than 2 months following sub-conjunctival implantation. 
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